Chlorpheniramine and ranitidine
ApprovedSmall molecule
Chlorpheniramine and ranitidine is one of 27 small molecule programs targeting Hypotension. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
136 competitors in Hypotension
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Phase 3
Firazyr
TakedaPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Midodrine Hydrochloride
TakedaPhase 3
Northera
LundbeckPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
L-Carnitine
IIperboreal Pharma Srl
Phase 3
Osmitrol
BB. Braun Medical Inc.
Phase 2
Bronitin Mist
LLongeveron Inc.
Phase 3
Chlorpheniramine and ranitidine
MMahidol University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- MMahidol University